Malignant News and Research

RSS

Viragen announces European Multiferon licensing agreement

Viragen and its majority-owned subsidiary, Viragen International have announced that a licensing agreement has been completed with Swedish Orphan International AB, granting exclusive marketing rights to Multiferon (multi-subtype, human alpha interferon) for the European Union (excluding previously licensed member states).

19 Apr 2007

New discoveries about stem cells in leukemia, breast and colon cancer

Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. With each new study, scientists are learning more about cancer-initiating properties of stem cells at organ sites and throughout the body.

19 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

Cortical mapping helps brain tumor removal

In 2006, it was estimated that 18,820 new cases were diagnosed and 12,820 deaths were associated with malignant tumors of the brain and other parts of the central nervous system.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

New diagnostic technologies to predict and monitor cancer risks

Molecular messages and signals circulating in blood or contained in cells lining the airway can identify early stage cancer, according to research reported at the 2007 Annual Meeting of the American Association for Cancer Research.

16 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

New, potentially more accurate method for diagnosing breast cancer

By combining two techniques, magnetic resonance imaging (MRI) and near-infrared optics, researchers at Dartmouth College and Dartmouth Medical School may have devised a new, potentially more accurate method for diagnosing breast cancer.

14 Apr 2007

Study suggests reason for high incidence of cancer in the prostate

Cancer occurs more frequently in the prostates of men than in any organ other than the skin. While DNA damage caused by exposure to the sun is likely the cause of many skin cancers, the cause of prostate cancer remains largely unknown.

12 Apr 2007

Oncolytics Biotech to proceed with phase II Sarcoma trial

Oncolytics Biotech has announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung.

11 Apr 2007